Waters has acquired the Rapid Evaporative Ionization Mass Spectrometry (REIMS) technology from MediMass. REIMS is an ionization technique that can be used as a source for direct analysis of samples by mass spectrometry. The REIMS technology represents substantially all of the assets of MediMass and includes patent applications, software, databases, and REIMS expertise.
Waters' experience with REIMS technology stems from a three-year collaboration among Waters, MediMass, and Imperial College London focused on advancing REIMS.
“While showing promise across many applications, REIMS technology significantly strengthens Waters’ technology position within health sciences,” said Rohit Khanna, vice president, worldwide marketing and informatics at Waters. “This technology acquisition along with our recent agreement with Prosolia for the exclusive rights to Desorption Electrospray Ionization (DESI) technology in clinical applications are key components in our burgeoning health sciences initiative. Both direct-from-sample ion source technologies are strategic discriminators as we look to grow the impact of mass spectrometry throughout the health sciences continuum.”
REIMS is the enabling technology for the “Intelligent Knife” or “iKnife,” a device in the conceptual stages of development that could potentially be used for real-time diagnostics in surgery.